8-K: Scorpius Holdings Announces Public Offering, Navigates NYSE American Exception

Scorpius Holdings plans a public offering of 12.5 million shares at $1.00 per share, utilizing a financial viability exception from NYSE American shareholder approval rules after an initial underwriting agreement was terminated.

Summary

• Scorpius Holdings intends to raise approximately $12.5 million through a public offering of 12.5 million shares of common stock, or pre-funded warrants, at $1.00 per share.
• The company initially entered into an underwriting agreement with ThinkEquity LLC, but it was terminated due to the suspension of trading of Scorpius's common stock on the NYSE American.
• The NYSE American has granted Scorpius a financial viability exception, allowing the company to proceed with the offering without shareholder approval.
• The company's audit committee determined that delaying the offering for shareholder approval would jeopardize the company's financial viability.
• The offering is expected to close around August 21, 2024, ten days after mailing a notification letter to shareholders.
• Scorpius expects to use the net proceeds from the offering for working capital and general corporate purposes.
• Preliminary unaudited results for the quarter ended June 30, 2024, indicate revenue between $0.3 million and $0.8 million, an operating loss between $8.6 million and $9.1 million, and a net loss before income taxes between $9.2 million and $9.7 million.
• As of June 30, 2024, the company had approximately $1.5 million in cash and cash equivalents and short-term investments and needs to raise additional capital to fund operations.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the termination of the initial underwriting agreement, the need for a financial viability exception, significant losses, and low cash reserves. While the company is attempting to raise capital, the overall situation suggests significant financial challenges.

Positives

• The company has secured a financial viability exception from the NYSE American, allowing it to proceed with a critical capital raise.
• The company intends to use the proceeds to fund working capital and general corporate purposes.
• The company has commenced microbial cGMP manufacturing in July 2024 and anticipates commencing mammalian cGMP manufacturing in the third quarter of 2024, which are expected to generate larger contracts than process development contracts.

Negatives

• The initial underwriting agreement was terminated due to a trading halt on the NYSE American.
• The company's preliminary unaudited results for Q2 2024 show a significant operating and net loss.
• The company has low cash reserves and needs to raise additional capital to fund operations.
• There is no assurance that the company will be able to consummate the offering under the current terms or at all.

Risks

• There is no guarantee that the company will be able to complete the public offering under the current terms or at all.
• The company's financial viability is at risk, as indicated by the need for a financial viability exception from the NYSE American.
• The company's preliminary unaudited financial results for Q2 2024 show significant losses.
• The company's cash reserves are low, and it needs to raise additional capital to fund operations.
• The company is subject to risks described in its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company intends to complete the public offering and use the proceeds for working capital and general corporate purposes. There is no assurance that the company will be able to consummate the offering under the current terms or at all.

Management Comments

• The Audit Committee of the Company's Board of Directors determined that the delay associated with obtaining a shareholder vote prior to consummation of the Offering and the issuance of the Securities would seriously jeopardize the financial viability of the Company.
• The company is mailing a letter to all shareholders not later than 10 days prior to the anticipated closing of the financing to alert investors that the Company will not seek, and will not be required to seek, the shareholder approval that would otherwise be required under applicable NYSE American rules.

Industry Context

The company is operating in the competitive CDMO market, and the need for this capital raise highlights the challenges of funding growth in this sector. The company's focus on biologics and cell therapy programs aligns with current industry trends.

Comparison to Industry Standards

• The company's need for a financial viability exception and the termination of the initial underwriting agreement suggest potential challenges compared to more established CDMO companies.
• The preliminary Q2 2024 results indicate significant losses, which may be concerning compared to industry benchmarks for profitability.
• The company's cash position of $1.5 million is low compared to other CDMOs, which typically require substantial capital for operations and expansion.
• Companies like Catalent and Lonza, which are larger and more established CDMOs, have more robust financial positions and do not typically require such exceptions to raise capital.

Corporate Governance

Stakeholder Impact

• Shareholders will be diluted by the issuance of new shares.
• Employees may be impacted by the company's financial situation.
• Customers may be concerned about the company's ability to continue operations.
• Suppliers and creditors may be concerned about the company's ability to pay its obligations.

Next Steps

• The company will enter into a new underwriting agreement.
• The company will mail a notification letter to shareholders.
• The company intends to close the public offering around August 21, 2024.

Key Dates

Keywords

public offering, underwriting agreement, financial viability exception, NYSE American, common stock, pre-funded warrants, capital raise, working capital, cGMP manufacturing, Scorpius Holdings